News & Updates

Management of metastatic hormone-sensitive prostate cancer (mHSPC) continues to evolve as clinicians refine the use of androgen deprivation therapy (ADT) and/or chemotherapy in combination with androgen receptor pathway inhibitors (ARPIs) in routine clinical practice. At an advisory board meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the University of Lübeck in Germany and Dr Darren Poon of the Hong Kong Sanatorium & Hospital discussed updated strategies and shared case studies to illustrate use of optimal ARPI-based regimens in patients with mHSPC.

Management of metastatic hormone-sensitive prostate cancer (mHSPC) has transformed from androgen deprivation therapy (ADT) alone to the addition of chemotherapy and androgen receptor pathway inhibitors (ARPIs) to create more efficacious treatment regimens. At an industry-sponsored meeting organized by the Hong Kong Society of Uro-Oncology, Professor Axel Merseburger of the Department of Urology, University of Lübeck in Germany, and Ms Helen Chan, Principal Pharmacist of the Chinese University of Hong Kong Medical Centre in Hong Kong, explored how ARPI-associated advances can further optimize outcomes, not only by improving survival, but also by maintaining health-related quality of life (HRQoL) and minimizing adverse events (AEs) and critical drug–drug interactions (DDIs).